RecruitingPhase 1NCT05717699

Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

Sponsor

Capital Medical University

Enrollment

18 participants

Start Date

Jan 4, 2023

Study Type

INTERVENTIONAL

Conditions

Adverse Drug Event Diffuse Intrinsic Pontine Glioma Oncolytic Virus

Summary

This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in progressive DIPG patients (NCI-CTCAE V5.0).

Eligibility

Min Age: 1 YearMax Age: 18 Years

Inclusion Criteria8

Informed consent of the parents or patient.
After surgical resection, biopsy, chemotherapy, or radiation therapy, tumor progression must be confirmed by MRI scan.
Biopsy is performed prior to injection of Ad-TD-nsIL12 to confirm DIPG (frozen section-based).
Pre-enrollment patients LPS (patients aged ≥1 and \<16 years) and KPS (patients aged ≥16 years) ≥ 50.
Patient must be, in the investigator opinion, able to comply with all the protocol procedures.
Age 1-18 years.
A negative pregnancy test in fertile women (women are considered of childbearing potential (WOCBP) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
Lesion considered by the investigator to be accessible for stereotactic biopsy.

Exclusion Criteria14

Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Patients must be afebrile (\<38℃) at the time of viral therapy.
Other investigational medications within 30 days prior to viral treatment.
Participants with immunodeficiency, autoimmune disease, or active hepatitis.
Any medical or psychological condition that might interfere with the patient's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.
Tumor with multiple location.
Pregnant or breast-feeding females.
Severe bone marrow hypoplasia.
Transaminases (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin \> 3 times the upper limit of normal.
Neutrophils \< 1x10\^9/L.
Platelets ≤ 100x10\^9/L.
Hemoglobin \< 9g/dl.
Patients with Li-Fraumini syndrome or a known germline defect in the retinoblastoma gene or its associated pathways.
Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration.
Blood transfusions or drugs (such as G-CSF) within 28 days before viral treatment to treat pancytopenia or other hematological disorders.

Interventions

BIOLOGICALAd-TD-nsIL12

After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.